Regorafenib (REG) combined with irinotecan (IRI) versus IRI alone as second-line treatment in patients with metastatic gastro-oesophageal adenocarcinomas (mGA): A randomized phase II trial (PRODIGE 58 – UCGI 35 – REGIRI).

Autor: Samalin, Emmanuelle, Senellart, Hélène, Evesque, Ludovic, Bouché, Olivier, Khemissa, Faiza, De La Fouchardiere, Christelle, Lopez, Anthony, Dermeche, Slimane, Botsen, Damien, Tougeron, David, Zaanan, Aziz, BEN Abdelghani, Meher, Guardiola, Emmanuel, Dubreuil, Olivier, Le Brun Ly, Valérie, Hennequin, Audrey, De Sousa Carvalho, Nicolas, Castan, Florence, Turpin, Anthony
Zdroj: Journal of Clinical Oncology; 2/1/2023 Supplement 1, Vol. 41, p387-387, 1p
Databáze: Supplemental Index